NCT06659276 Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma
| NCT ID | NCT06659276 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Multiple Myeloma |
| Study Type | OBSERVATIONAL |
| Enrollment | 83 participants |
| Start Date | 2022-09-01 |
| Primary Completion | 2024-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 83 participants in total. It began in 2022-09-01 with a primary completion date of 2024-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective is to evaluate the concordance of FDG PET/CT and total body DWI MRI sequences performed during staging and at the completion of therapy. Specifically, we will assess the positivity rates, both patient-based and lesion-based (total and by district), of the two methods during staging and at the completion of therapy. An interim analysis will be conducted comparing the two methods, followed by a final prognostic analysis.
Eligibility Criteria
Inclusion Criteria: * • Patients with symptomatic myeloma in the staging phase or with suspected symptomatic myeloma in the diagnostic phase * Patients who have signed the informed consent form Exclusion Criteria: * Patients simultaneously affected by other neoplastic diseases or with a history of other neoplasms in the previous 5 years * Age \< 18 years * Women who are breastfeeding or pregnant * Patients with metal implants or devices that constitute an absolute contraindication for MRI * Patients with severe claustrophobia * Patients with bone pain that prevents prolonged maintenance of the supine position
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06659276 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06659276 currently recruiting?
Yes, NCT06659276 is actively recruiting participants. Contact the research team at cristina.nanni@aosp.bo.it for enrollment information.
Where is the NCT06659276 trial being conducted?
This trial is being conducted at Bologna, Italy.
Who is sponsoring the NCT06659276 clinical trial?
NCT06659276 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 83 participants.